Edition:
United Kingdom

Selvita SA (SLVP.WA)

SLVP.WA on Warsaw Stock Exchange

53.20PLN
4:00pm BST
Change (% chg)

-0.30zł (-0.56%)
Prev Close
53.50zł
Open
53.60zł
Day's High
53.60zł
Day's Low
52.50zł
Volume
296
Avg. Vol
7,964
52-wk High
65.00zł
52-wk Low
39.00zł

Latest Key Developments (Source: Significant Developments)

Selena Q2 Net Profit Rises To 15.1 Million Zlotys
Sunday, 23 Sep 2018 

Sept 24 (Reuters) - SELENA FM SA ::Q2 REVENUE 332.3 MILLION ZLOTYS VERSUS 321.0 MILLION ZLOTYS A YEAR AGO.Q2 NET PROFIT IS 15.1 MILLION ZLOTYS VERSUS 3.6 MILLION ZLOTYS A YEAR AGO.Q2 EBITDA AT 25 MILLION ZLOTYS VERSUS 26 MILLION ZLOTYS A YEAR AGO.Q2 OPERATING PROFIT 18.0 MILLION ZLOTYS VERSUS 19.4 MILLION ZLOTYS A YEAR AGO.  Full Article

Selvita H1 Net Profit Up At 15.9 Mln Zlotys
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - SELVITA SA ::REPORTED ON WEDNESDAY H1 NET PROFIT OF 15.9 MILLION ZLOTYS VERSUS 8.0 MILLION ZLOTYS YEAR AGO.H1 OPERATING REVENUE 50.5 MILLION ZLOTYS VERSUS 59.7 MILLION ZLOTYS YEAR AGO.  Full Article

Selvita Q1 Net Profit Up At 20.0 Mln Zlotys
Wednesday, 23 May 2018 

May 23 (Reuters) - SELVITA SA ::REPORTED ON TUESDAY Q1 NET PROFIT OF 20.0 MILLION ZLOTYS VERSUS 5.2 MILLION ZLOTYS YEAR AGO .Q1 OPERATING REVENUE 23.3 MILLION ZLOTYS VERSUS 26.8 MILLION ZLOTYS YEAR AGO .Q1 EBITDA 0.8 MILLION ZLOTYS VERSUS 8.6 MILLION ZLOTYS YEAR AGO .  Full Article

Selvita Plans Series H Share Issue In Q1
Monday, 22 Jan 2018 

Jan 22 (Reuters) - SELVITA SA ::PLANS TO OFFER UP TO 2.2 MILLION NEWLY ISSUED SERIES H SHARES AND EXPECTS TO RAISE UP TO 140 MILLION ZLOTYS NET, THE COMPANY SAYS IN A STATEMENT.THE OFFERING IS PLANNED FOR Q1, SUBJECT TO THE MARKET SITUATION .FUNDS RAISED WILL BE USED FOR THE DEVELOPMENT OF INNOVATIVE PROJECTS WITH A STRONG COMMERCIALIZATION POTENTIAL.SELVITA PREDICTS THAT TOTAL FINANCIAL EXPENSES ASSOCIATED WITH ITS INVESTMENT PLANS FOR 2017-2021 WILL AMOUNT TO ABOUT 390 MILLION ZLOTYS.CO PLANS TO RAISE 140 MLN ZLOTYS FROM INVESTORS, WITH THE REMINDER COMING FROM GRANTS AND OWN FUNDS.IN SEPT. 2017, SELVITA FILED A PROSPECTUS FOR THE ISSUE OF UP TO 2.2 MLN SERIES H SHARES nL8N1LM0KT.  Full Article

Selvita Says FDA Allows To Resume Clinical Trial Of SEL24
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Selvita SA ::SAID ON SATURDAY THE FOOD AND DRUG ADMINISTRATION (FDA) HAS ALLOWED THE COMPANY TO RESUME CLINICAL TRIAL OF SEL24 PHASE I/II, CARRIED OUT IN U.S. WITH PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA.FDA TEMPORARILY SUSPENDED THE TRIAL AFTER "SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTION".FDA DECISION ALLOWS TO CONTINUE SEL24 CLINICAL TRIAL, AFTER CHANGING THE TRIAL'S PROTOCOL, INCLUDING ADJUSTING THE DOSING SCHEDULE TO THE STANDARD 3 + 3, AS RECOMMENDED BY FDA.MODIFICATION OF THE CLINICAL TRIAL PLAN REQUIRES THE APPROVAL OF THE ETHICS COMMITTEES IN THE INDIVIDUAL RESEARCH CENTERS (INSTITUTIONAL REVIEW BOARD).THE COMPANY IS WORKING ON THIS TOGETHER WITH DOCTORS CONDUCTING RESEARCH IN INDIVIDUAL CENTERS AND WITH THE MENARINI GROUP.  Full Article

Selvita: FDA suspends clinical trial of SEL24 after patient death
Monday, 9 Oct 2017 

Oct 9 (Reuters) - SELVITA SA ::SAID ON SATURDAY THAT FOOD AND DRUG ADMINISTRATION (FDA) ORDERED SUSPENSION OF CLINICAL TRIAL OF SEL24 .FDA ISSUED DECISION AFTER THE DEATH OF PATIENT FOLLOWING A STROKE THAT HAD PREVIOUSLY OCCURRED AND WAS REPORTED AS SUSPECTED SERIOUS UNEXPECTED ADVERSE REACTION.COMPANY INFORMED ABOUT ADMITTING ITS PRODUCT SEL24 TO CLINICAL TRIALS BY FDA IN AUGUST nFWN1AZ06I.COMPANY TO WORK CLOSELY WITH FDA TO RESUME THE STUDY AS SOON AS POSSIBLE BY PROVIDING ADDITIONAL DATA AND INTRODUCING AMENDMENTS IN TRIAL PROTOCOL.  Full Article

BRIEF-Selena Q2 Net Profit Rises To 15.1 Million Zlotys

* Q2 REVENUE 332.3 MILLION ZLOTYS VERSUS 321.0 MILLION ZLOTYS A YEAR AGO